Compare GSK plc (GSK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs State Street SPDR S&P Biotech ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: GSK plc is far larger — about 9.1× State Street SPDR S&P Biotech ETF's market cap, and GSK plc pays a 3.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GSK | XBI | |
|---|---|---|
Market Cap | $91.88B | $10.11B |
Volume | 7,730,529 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $169.55 |
52-Week Low | $43.24 | $104.99 |
Typical Hold Time | 93 Days | 38 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
